Share Price and Basic Stock Data
Last Updated: October 28, 2025, 3:58 pm
| PEG Ratio | 310.74 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Biogen Pharmachem Industries Ltd operates within the finance and investments sector, with its stock priced at ₹0.83 and a market capitalization of ₹74.9 Cr. The company’s revenue trends over recent quarters show a fluctuating performance, with sales recorded at ₹0.75 Cr in June 2023 and ₹0.78 Cr in March 2024, before rising to ₹1.35 Cr by March 2025. However, the company has faced challenges, as evidenced by negative sales figures in multiple previous quarters, including ₹-1.54 Cr in June 2022 and ₹-0.00 Cr in September 2022. This inconsistency highlights the volatile nature of the company’s revenue generation, which is critical for stakeholder assessment. The trailing twelve months (TTM) revenue stood at ₹3.12 Cr, indicating a slight recovery compared to preceding years. The company reported significant operational volatility, which can be attributed to market conditions affecting its investment activities. Overall, while there are signs of revenue recovery, the historical performance necessitates a cautious approach for investors.
Profitability and Efficiency Metrics
Biogen Pharmachem’s profitability metrics reveal a complex financial landscape. The company recorded a net profit of ₹1.21 Cr, with a price-to-earnings (P/E) ratio of 61.9, suggesting a relatively high valuation compared to earnings. Operating profit margin (OPM) stood at an impressive 87.01% in the latest reporting period, indicating strong operational efficiency and cost management. However, profitability has been inconsistent, with operating profit recorded at ₹0.41 Cr in June 2023, followed by a significant rise to ₹1.18 Cr by March 2025. The return on equity (ROE) and return on capital employed (ROCE) both hovered around 0.39%, reflecting limited returns on shareholders’ funds and capital employed. The interest coverage ratio (ICR) remained at 0.00x, indicating that the company does not currently incur interest expenses, which could be a double-edged sword, as it may reflect a lack of leverage for growth. Overall, while the operating margin is commendable, the volatility in profitability poses challenges for sustainable growth.
Balance Sheet Strength and Financial Ratios
Biogen Pharmachem’s balance sheet presents a mix of strengths and weaknesses. The company reported total assets of ₹92.02 Cr for March 2025, supported by reserves of ₹26.67 Cr, marking a significant recovery from negative reserves in previous years. The absence of borrowings, recorded at ₹0.00 Cr, highlights a conservative financial strategy, reducing financial risk but potentially limiting growth opportunities. The current ratio stood at an impressive 29.65x, suggesting robust short-term liquidity, which is considerably higher than typical sector norms. However, the company’s equity capital remained static at ₹65.26 Cr, raising questions about its capital raising strategies. The price-to-book value (P/BV) ratio of 0.68x indicates that the stock is trading at a discount to its book value, which may attract value investors. Despite the positive liquidity position, the lack of growth in equity and reliance on historical performance could hinder long-term financial stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Biogen Pharmachem Industries Ltd indicates a fully public ownership structure, with 100% public shareholding across recent reporting periods. The number of shareholders has varied, with a peak of 3,03,780 reported in December 2024, but declining to 2,98,703 by June 2025. This fluctuation suggests changing investor sentiment, potentially influenced by the company’s financial performance and market conditions. The absence of institutional investments (FIIs and DIIs) may reflect a lack of confidence among larger investors, which could impact the stock’s liquidity and price stability. The company’s ability to attract institutional investment could be crucial for future growth, as institutional investors often bring not only capital but also strategic guidance. Overall, while the public ownership structure reflects a broad base of retail investors, the lack of institutional backing may pose challenges to long-term investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Biogen Pharmachem’s outlook remains contingent on its ability to stabilize revenue generation and profitability. Key strengths include a solid operating profit margin and a strong liquidity position, which can provide a buffer against market volatility. However, risks persist, including historical revenue fluctuations and the absence of institutional investment, which may affect market confidence. The company must focus on enhancing its operational efficiency and addressing profitability volatility to attract a broader investor base. Additionally, the lack of debt could be either a strength or a limitation, depending on future growth strategies. In scenarios where the company successfully executes its operational plans, it may see improved market performance and investor sentiment. Conversely, failure to maintain consistent profitability could lead to further declines in shareholder confidence and market performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Biogen Pharmachem Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modern Shares & Stockbrokers Ltd | 11.7 Cr. | 40.0 | 67.7/36.4 | 41.9 | 43.5 | 0.00 % | 3.32 % | 1.74 % | 10.0 |
| Monarch Networth Capital Ltd | 2,448 Cr. | 309 | 495/280 | 15.8 | 102 | 0.32 % | 33.3 % | 26.2 % | 10.0 |
| Monotype India Ltd | 38.7 Cr. | 0.55 | 2.42/0.46 | 3.76 | 0.02 | 0.00 % | 286 % | % | 1.00 |
| Multipurpose Trading & Agencies Ltd | 4.19 Cr. | 8.47 | 12.7/8.25 | 10.3 | 0.00 % | 3.68 % | 3.38 % | 10.0 | |
| Munoth Financial Services Ltd | 28.8 Cr. | 56.2 | 72.0/47.6 | 20.6 | 0.00 % | 2.41 % | 3.38 % | 10.0 | |
| Industry Average | 6,822.91 Cr | 1,424.34 | 135.36 | 3,769.50 | 0.31% | 21.70% | 14.20% | 7.28 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -1.54 | -0.00 | -0.00 | -0.01 | 0.75 | -0.00 | -0.00 | 0.78 | -0.09 | -0.00 | 0.23 | 1.35 | 1.54 |
| Expenses | 0.05 | 0.11 | 0.03 | 0.19 | 0.34 | 0.04 | 0.03 | 0.04 | 0.07 | 0.35 | 0.54 | 0.17 | 0.20 |
| Operating Profit | -1.59 | -0.11 | -0.03 | -0.20 | 0.41 | -0.04 | -0.03 | 0.74 | -0.16 | -0.35 | -0.31 | 1.18 | 1.34 |
| OPM % | 54.67% | 94.87% | -134.78% | 87.41% | 87.01% | ||||||||
| Other Income | -0.00 | 2.05 | 0.33 | -0.00 | -0.00 | 0.76 | 0.09 | -0.00 | -0.00 | -0.65 | -0.00 | -0.00 | -0.00 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Profit before tax | -1.59 | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 | 1.34 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Net Profit | -1.59 | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 | 1.34 |
| EPS in Rs | -0.02 | 0.03 | 0.00 | -0.00 | 0.01 | 0.01 | 0.00 | 0.01 | -0.00 | -0.02 | -0.00 | 0.02 | 0.01 |
Last Updated: August 1, 2025, 6:10 am
Below is a detailed analysis of the quarterly data for Biogen Pharmachem Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1.54 Cr.. The value appears strong and on an upward trend. It has increased from 1.35 Cr. (Mar 2025) to 1.54 Cr., marking an increase of 0.19 Cr..
- For Expenses, as of Jun 2025, the value is 0.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Mar 2025) to 0.20 Cr., marking an increase of 0.03 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For OPM %, as of Jun 2025, the value is 87.01%. The value appears to be declining and may need further review. It has decreased from 87.41% (Mar 2025) to 87.01%, marking a decrease of 0.40%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.02 (Mar 2025) to 0.01, marking a decrease of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:45 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0.00 | -0.00 | -0.00 | -0.00 | 0.11 | 0.95 | -0.00 | 1.62 | 2.47 | -0.00 | 2.38 | 1.20 | 3.12 |
| Expenses | 0.03 | 0.04 | 0.03 | 0.12 | 6.72 | 0.95 | 0.12 | 3.22 | 2.49 | 0.45 | 0.45 | 1.49 | 1.26 |
| Operating Profit | -0.03 | -0.04 | -0.03 | -0.12 | -6.61 | -0.00 | -0.12 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 | 1.86 |
| OPM % | -6,009.09% | -0.00% | -98.77% | -0.81% | 81.09% | -24.17% | 59.62% | ||||||
| Other Income | -0.00 | -0.00 | -0.00 | -0.00 | 0.05 | -0.00 | -0.00 | -0.00 | 0.01 | 0.91 | -0.00 | -0.00 | -0.65 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Depreciation | 0.10 | 0.10 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Profit before tax | -0.13 | -0.14 | -0.03 | -0.12 | -6.56 | -0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.21 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | ||
| Net Profit | -0.13 | -0.13 | -0.03 | -0.12 | -6.56 | -0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.21 |
| EPS in Rs | -0.00 | -0.00 | -0.00 | -0.00 | -0.10 | -0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 | 0.01 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 76.92% | -300.00% | -5366.67% | 100.00% | -1233.33% | 99.38% | 4700.00% | 319.57% | -115.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.92% | -376.92% | -5066.67% | 5466.67% | -1333.33% | 1332.71% | 4600.62% | -4380.43% | -434.59% |
Biogen Pharmachem Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -21% |
| TTM: | 352% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 30% |
| 3 Years: | -2% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: July 25, 2025, 1:41 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 |
| Reserves | -4.14 | -4.27 | -4.30 | -4.42 | -10.98 | -10.99 | -9.51 | -11.12 | -11.13 | -10.67 | -8.74 | 26.67 |
| Borrowings | 57.21 | 10.00 | 6.21 | 0.72 | 0.01 | 0.63 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 4.93 | 2.49 | 1.64 | 1.69 | 1.64 | 2.73 | 0.03 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 |
| Total Liabilities | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 60.86 | 43.78 | 26.69 | 22.39 | 3.52 | 6.25 | 6.45 | 9.49 | 6.95 | 8.85 | 5.44 | 23.84 |
| Other Assets | 62.40 | 29.70 | 42.12 | 40.86 | 52.41 | 51.38 | 49.64 | 44.76 | 48.00 | 45.98 | 51.38 | 68.18 |
| Total Assets | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 |
Below is a detailed analysis of the balance sheet data for Biogen Pharmachem Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 65.26 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 65.26 Cr..
- For Reserves, as of Mar 2025, the value is 26.67 Cr.. The value appears strong and on an upward trend. It has increased from -8.74 Cr. (Mar 2024) to 26.67 Cr., marking an increase of 35.41 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.09 Cr.. The value appears to be improving (decreasing). It has decreased from 0.30 Cr. (Mar 2024) to 0.09 Cr., marking a decrease of 0.21 Cr..
- For Total Liabilities, as of Mar 2025, the value is 92.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 56.82 Cr. (Mar 2024) to 92.02 Cr., marking an increase of 35.20 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 23.84 Cr.. The value appears strong and on an upward trend. It has increased from 5.44 Cr. (Mar 2024) to 23.84 Cr., marking an increase of 18.40 Cr..
- For Other Assets, as of Mar 2025, the value is 68.18 Cr.. The value appears strong and on an upward trend. It has increased from 51.38 Cr. (Mar 2024) to 68.18 Cr., marking an increase of 16.80 Cr..
- For Total Assets, as of Mar 2025, the value is 92.02 Cr.. The value appears strong and on an upward trend. It has increased from 56.82 Cr. (Mar 2024) to 92.02 Cr., marking an increase of 35.20 Cr..
Notably, the Reserves (26.67 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -57.24 | -10.04 | -6.24 | -0.84 | -6.62 | -0.63 | -0.43 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Working Capital Days | 23,194.09 | 2,651.05 | 549.75 | 152.21 | -35.27 | 170.33 | ||||||
| ROCE % | -0.14% | -0.15% | -0.04% | -0.19% | -11.32% | 0.00% | -0.22% | -2.90% | -0.02% | -0.37% | 3.47% | -0.39% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Diluted EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Cash EPS (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 |
| PBDIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Net Profit / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Return on Networth / Equity (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return on Capital Employeed (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return On Assets (%) | -0.31 | 3.39 | 0.83 | -0.01 | -2.95 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| Current Ratio (X) | 29.65 | 0.30 | 0.64 | 2.37 | 23.64 |
| Quick Ratio (X) | 29.65 | 0.30 | 0.64 | 2.37 | 23.64 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Enterprise Value (Cr.) | 60.63 | 69.16 | 38.37 | 91.28 | 13.70 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.89 | 8.44 |
| EV / EBITDA (X) | -207.15 | 35.82 | 84.25 | -10849.12 | -8.54 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.93 | 8.45 |
| Price / BV (X) | 0.68 | 1.22 | 0.70 | 1.69 | 0.25 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.94 | 8.47 |
| EarningsYield | 0.00 | 0.02 | 0.01 | 0.00 | -0.11 |
After reviewing the key financial ratios for Biogen Pharmachem Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 15. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 10. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return On Assets (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 5. It has decreased from 3.39 (Mar 24) to -0.31, marking a decrease of 3.70.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 29.65. This value exceeds the healthy maximum of 3. It has increased from 0.30 (Mar 24) to 29.65, marking an increase of 29.35.
- For Quick Ratio (X), as of Mar 25, the value is 29.65. This value exceeds the healthy maximum of 2. It has increased from 0.30 (Mar 24) to 29.65, marking an increase of 29.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 60.63. It has decreased from 69.16 (Mar 24) to 60.63, marking a decrease of 8.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -207.15. This value is below the healthy minimum of 5. It has decreased from 35.82 (Mar 24) to -207.15, marking a decrease of 242.97.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 24) to 0.68, marking a decrease of 0.54.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biogen Pharmachem Industries Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.31% (Industry Average ROCE: 21.7%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.31% (Industry Average ROE: 14.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 29.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 61.9 (Industry average Stock P/E: 135.36)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Finance & Investments | Shop No. 8, First Floor, Makers - 1 Building, Rajkot Gujarat 360001 | suntechnooverseas@gmail.com http://www.biogenpharma.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kelash Bunkar | WholeTime Director & CFO |
| Mr. Chandrakant Govindbhai Parmar | Director |
| Mr. Chhayaben Parmar | Director |
| Mr. Narendrakumar Vaniya | Director |
| Mr. Aman Patel | Director |
| Mr. Harshadkumar Rathod | Director |
FAQ
What is the intrinsic value of Biogen Pharmachem Industries Ltd?
Biogen Pharmachem Industries Ltd's intrinsic value (as of 29 October 2025) is 0.28 which is 66.27% lower the current market price of 0.83, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 74.9 Cr. market cap, FY2025-2026 high/low of 1.36/0.75, reserves of ₹26.67 Cr, and liabilities of 92.02 Cr.
What is the Market Cap of Biogen Pharmachem Industries Ltd?
The Market Cap of Biogen Pharmachem Industries Ltd is 74.9 Cr..
What is the current Stock Price of Biogen Pharmachem Industries Ltd as on 29 October 2025?
The current stock price of Biogen Pharmachem Industries Ltd as on 29 October 2025 is 0.83.
What is the High / Low of Biogen Pharmachem Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biogen Pharmachem Industries Ltd stocks is 1.36/0.75.
What is the Stock P/E of Biogen Pharmachem Industries Ltd?
The Stock P/E of Biogen Pharmachem Industries Ltd is 61.9.
What is the Book Value of Biogen Pharmachem Industries Ltd?
The Book Value of Biogen Pharmachem Industries Ltd is 1.41.
What is the Dividend Yield of Biogen Pharmachem Industries Ltd?
The Dividend Yield of Biogen Pharmachem Industries Ltd is 0.00 %.
What is the ROCE of Biogen Pharmachem Industries Ltd?
The ROCE of Biogen Pharmachem Industries Ltd is 0.39 %.
What is the ROE of Biogen Pharmachem Industries Ltd?
The ROE of Biogen Pharmachem Industries Ltd is 0.39 %.
What is the Face Value of Biogen Pharmachem Industries Ltd?
The Face Value of Biogen Pharmachem Industries Ltd is 1.00.